The venture's drug resistance prediction technology fits the Drug Discovery Technologies and Informatics categories. The accelerator targets early-stage startups with prototypes, matching the venture's pre-seed stage and validated proof-of-concept. However, the program is US-based, while the founder targets EU/France, and the deadline has passed for 2026, so timing is a risk.